EP0882063A2 - Peptide antibacterien et antifongique - Google Patents

Peptide antibacterien et antifongique

Info

Publication number
EP0882063A2
EP0882063A2 EP97905217A EP97905217A EP0882063A2 EP 0882063 A2 EP0882063 A2 EP 0882063A2 EP 97905217 A EP97905217 A EP 97905217A EP 97905217 A EP97905217 A EP 97905217A EP 0882063 A2 EP0882063 A2 EP 0882063A2
Authority
EP
European Patent Office
Prior art keywords
peptide
active material
compositions
usable
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97905217A
Other languages
German (de)
English (en)
French (fr)
Inventor
Philippe Bulet
Charles Hetru
Jules Hoffmann
Laurence Sabatier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer CropScience SA
Original Assignee
Rhone Poulenc Agrochimie SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Agrochimie SA filed Critical Rhone Poulenc Agrochimie SA
Publication of EP0882063A2 publication Critical patent/EP0882063A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50Isolated enzymes; Isolated proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Definitions

  • the subject of the present invention is a new protein-rich peptide having antibacterial and antifungal properties, compositions which can be used in agriculture and in human or animal therapy containing this peptide as active material.
  • the invention also relates to methods of treating plants using these compositions as well as methods of preparing this peptide.
  • insects have an effective resistance against bacteria.
  • This defense is largely based on the rapid synthesis of several families of peptides. This defense is due to the rapid synthesis of several families of peptides with a broad spectrum of activity. This synthesis is induced by a septic injury or by the injection of a small dose of bacteria.
  • the antibacterial peptides induced the best characterized are the cecropins and defensins of insects.
  • Several other antibacterial peptides have been partially characterized.
  • Scorpions are animals older than insects on a philogenic level.
  • a first aspect of the invention relates to the peptide of formula I:
  • the molecule of formula I will be called androctonine.
  • This molecule contains 4 cysteine residues engaged in two intramolecular bridges.
  • Another aspect of the invention relates to a first method for obtaining and isolating the above peptide, which is characterized in that successively: a) the hemolymp of the scorpion Androctonus australis is taken; b) the extraction is carried out by bringing the hemolymph of Androctonus australis obtained previously into contact with an acid medium with stirring, then by centrifugation; c) the supernatant is fractionated with separation by washing of the hydrophilic molecules and elution of the hydrophobic molecules by suitable elements on a separating column d) the extracts are purified. e) characterizing the peptide.
  • the hemolymph is removed by cuticular incision. It is collected in a tube containing a protease inhibitor. After centrifugation to remove the blood cells, the plasma is stored at -30 ° C.
  • the second step (extraction) the hemolymph of Androctonus australis is brought into contact with an acid medium, consisting of an acid solution of an acid (pH 2).
  • the solution can be a solution of a mineral or organic acid such as, for example, trifluoroacetic acid.
  • the extract obtained is then centrifuged cold at a speed of 30,000 g at 4 ° C, for 25 min.
  • the extract is deposited on a reverse phase cartridge to carry out a solid phase extraction.
  • the water-soluble molecules are washed with a dilute acid solution and the hydrophobic molecules are eluted with an appropriate eluent. Good results are obtained with trifluoroacetic acid for washing and an eluent containing increasing amounts of acetonitrile in dilute acid solution.
  • the fourth step (purification) is carried out with a suitable eluent which may be different or identical to that of the previous phase.
  • a suitable eluent which may be different or identical to that of the previous phase.
  • the nature of the peptide is analyzed according to the method of sequencing by degradation of Edman (Acta Chemica Scandinavia 10 (1956) p; 761-768). According to this method, the following structures are obtained:
  • the measured masses of androctonine above are respectively: 3076.65 ⁇ 0.24 Da;
  • the mass defect corresponds to the formation of two intramolecular disulfide bridges.
  • the molecule was cleaved by an enzyme, the endoproteinase Lys-C, which breaks the peptide chain after lysine.
  • the peptides obtained were isolated and mass spectrometry showed that they were two peptides linked by a disulfide bridge.
  • the deduced sequences were Arg Ser Val Cys Arg Gin Ile Lys plus Cys Thr Asn Arg Asn Pro Tyr and Ile Cys Arg Arg Arg Gly Gly Cys Tyr Tyr.
  • the peptides according to the invention can also be obtained without difficulty according to a second method, by chemical synthesis FMOC (Atherton and Sheppard RC (1989), Solid Phase Peptide Synthesis (IRL, Oxford, UK) followed by renaturation in a 100 mM solution of ammonium acetate at pH 8.5 for 24 h with stirring at room temperature
  • the androctonine obtained has the same chromatographic properties as the native molecule and the connectivity of the disulfide bridges is identical to that of the natural molecule. measured after renaturation (3076, 61 ⁇ 0.67) is very similar to that of the native molecule.
  • the synthetic molecule has the same antibacterial activity as the native molecule on the bacterium Micrococcus liteus. All antibacterial and hemolytic tests are performed with the synthetic molecule.
  • Gram negative, and Gram negative see Table 1
  • phytopathogenic bacteria and phytopathogenic fungi.
  • Example 1 Isolation and characterization of the peptide the following steps are followed: - extraction and purification: The hemolymph (3.8 ml) is removed by incision from the cuticle. It is transferred to a tube kept cold in the presence of a protease inhibitor (aprotinin) and then centrifuged at 30,000 g for 25 minutes at 4 ° C. The supernatant thus obtained is immediately subjected to the various stages of purification. Fractionation of the extract on Sep-Pak CJ8 cartridges After depositing the extract on Sep-Pak C ⁇ g cartridges, the hydrophilic molecules are eliminated by a simple washing with 5 ml of acidified water with trifluoacetic acid (TFA) at 0.05%.
  • TFA trifluoacetic acid
  • Aquapore OD 300 Ci8 with a linear gradient of 2 to 52% acetonitrile in acidified water (TFA at 0.05%) in 90 minutes (i.e. an increase of 0.44% of acetonitrile per minute) for a flow rate 1 ml / min.
  • HPI High Pressure Inert
  • the elution is carried out in a linear biphasic gradient of acetonitrile from 2 to 11% in acidified water (6 mM HCl) in 10 minutes and from 11 to 21% in 50 min at a flow rate of 1 ml / min.
  • the purity of the active fraction is controlled by capillary electrophoresis before determining the sequence by Edman degradation and analysis by mass spectrometry.
  • PB medium Poor Broth, Luria Bertani medium devoid of yeast extract
  • DIFCO yeast extract
  • the bacteria to be tested are brought to an optical density at 600 nm of 0.001 in a fresh culture medium.
  • LOul of each fraction is deposited in microtiter plates in the presence of 100 ⁇ l of the bacterial suspension. After 24 hours of incubation at 25 ° C., the growth is evaluated by measuring the absorbance at 600 nm using a microtiter plate reader. Under these conditions, 50% inhibition is observed at the concentrations, expressed in ⁇ M, indicated in the following table:
  • cultures which can be the subject of an antibacterial treatment using a compound according to the invention mention may be made, for example, of rice, cereals, in particular wheat and barley, as well as arboreal, fruit and vegetable plants.
  • cultures which can be the subject of an antifungal treatment with the aid of a compound according to the invention mention may be made, by way of examples, of cucurbits, floral crops (petunia), and vegetable crops. (carrots, tomatoes, cabbage).
  • the present invention also relates to compositions, usable as antibacterial agents, containing as active material (s) one (or more) compound according to the invention as described above, in admixture with solid or liquid carriers, acceptable in agriculture and surfactants also acceptable in agriculture.
  • active material s
  • solid or liquid carriers acceptable in agriculture and surfactants also acceptable in agriculture.
  • surfactants also acceptable in agriculture.
  • these compositions cover not only the compositions ready to be applied to the culture to be treated by means of a suitable device, such as a spraying device, but also the concentrated commercial compositions which must be diluted before application to the culture.
  • compositions can also contain all kinds of other ingredients such as, for example, protective colloids, adhesives, thickeners, thixotropic agents, penetration agents, stabilizers, sequestrants, etc. More generally the compounds used in the invention can be combined with all the solid or liquid additives corresponding to the usual techniques of formulation.
  • compositions according to the invention usually contain from 0.05 to 95% approximately (by weight) of a compound according to the invention (hereinafter called active material), one or more solid or liquid carriers and, optionally, one or more surfactants.
  • support in the present description, is meant an organic or mineral, natural or synthetic material, with which the compound is combined to facilitate its application to the plant, to seeds or to the soil.
  • This support is therefore generally inert and it must be acceptable in agriculture, in particular on the treated plant.
  • the support can be solid (clays, natural or synthetic silicates, silica, resins, waxes, solid fertilizers, etc.) or liquid (water, alcohols, in particular butanol, etc.).
  • the surfactant can be an emulsifying, dispersing or wetting agent of ionic or nonionic type or a mixture of such surfactants. Mention may be made, for example, of salts of polyacrylic acids, salts of lignosulfonic acids, salts of phenolsulfonic or naphthalene sulfonic acids, polycondensates of ethylene oxide on fatty alcohols or on fatty acids or on fatty amines , substituted phenols (in particular alkylphenols or arylphenols), ester salts sulfosuccinic acids, taurine derivatives (in particular alkyltaurates), phosphoric esters of polyoxyethylated alcohols or phenols, esters of fatty acids and polyols, the derivatives containing sulfates, sulfonates and phosphates of the above compounds.
  • the presence of at least one surfactant is generally essential when the compound and / or the inert support
  • compositions for agricultural use according to the invention can contain the active materials according to the invention within very wide limits, ranging from 0.05% to 95% (by weight).
  • Their content of surfactant is advantageously between 5% and 40% by weight.
  • compositions according to the invention are themselves in fairly diverse forms, solid or liquid.
  • dusting powders with compound content of up to 100%
  • granules in particular those obtained by extrusion, by compacting, by impregnation of a granulated support, by from a powder (the compound content in these granules being between 0.5 and 80% for the latter cases), the effervescent tablets or tablets.
  • the peptide according to the invention can also be used in the form of powders for dusting; one can also use a composition comprising 50 g of active material and 950 g of talc; one can also use a composition comprising 20 g of active material, 10 g of finely divided silica and 970 g of talc; these constituents are mixed and ground and the mixture is applied by dusting.
  • liquid compositions or intended to constitute liquid compositions during application, mention may be made of solutions, in particular water-soluble concentrates, emulsifiable concentrates, emulsions, concentrated suspensions, aerosols, powders wettable (or spray powder), pastes, gels.
  • solutions in particular water-soluble concentrates, emulsifiable concentrates, emulsions, concentrated suspensions, aerosols, powders wettable (or spray powder), pastes, gels.
  • the emulsifiable or soluble concentrates most often comprise 10 to 80% of active material, the emulsions or solutions ready for application containing, for their part, 0.001 to 20% of active material.
  • the emulsifiable concentrates can contain, when necessary, 2 to 20% of suitable additives such as stabilizers, surfactants, penetration agents, corrosion inhibitors, dyes or adhesives previously cited.
  • emulsions with any desired concentration can be obtained by dilution with water, which are particularly suitable for application to crops.
  • emulsifiable concentrates here is the composition of some emulsifiable concentrates:
  • the concentrated suspensions are prepared so as to obtain a stable fluid product which does not deposit and they usually contain from 10 to 75% of active material, from 0.5 to 15% of surfactants, from 0 , 1 to 10% of thixotropic agents, 0 to 10% of suitable additives, such as defoamers, corrosion inhibitors, stabilizers, penetrating agents and adhesives and, as support, water or an organic liquid in which the active ingredient is sparingly or not very soluble: certain organic solids or mineral salts can be dissolved in the support to help prevent sedimentation or as antifreeze for water.
  • Example SC 1 - active ingredient 500 g
  • Wettable powders are usually prepared so that they contain 20 to 95% of active ingredient, and they usually contain, in addition to the solid support, 0 to 30% of a wetting agent, 3 20% of a dispersing agent, and, when necessary, 0.1 to 10% of one or more stabilizers and / or other additives, such as penetrating agents, adhesives, or anti-caking agents, dyes, etc ...
  • the active ingredients are intimately mixed in the appropriate mixers with the additional substances and ground with mills or other suitable grinders.
  • pasta can be made.
  • the conditions and methods of making and using these pastes are similar to those of wettable powders or spraying powders.
  • compositions of wettable powders As an example, here are various compositions of wettable powders (or spraying powders):
  • This wettable powder contains the same ingredients as in the previous example, in the following proportions: - active material 75%
  • aqueous dispersions and emulsions for example the compositions obtained by diluting with water a wettable powder or an emulsifiable concentrate according to the invention, are included in the general scope of the present invention.
  • the emulsions can be of the water-in-oil or oil-in-water type and they can have a thick consistency like that of a "mayonnaise".
  • the compounds according to the invention can be formulated in the form of water-dispersible granules also included within the scope of the invention.
  • the active material content of these granules is generally between approximately 1% and 90%, and preferably between 25% and 90%.
  • the rest of the granule is essentially composed of a solid filler and optionally surfactant additives giving the granule properties of dispersibility in water.
  • These granules can be essentially of two distinct types depending on whether the selected filler is soluble or not in water.
  • the filler When the filler is water-soluble, it can be mineral or, preferably, organic. We got excellent results with urea.
  • an insoluble filler it is preferably mineral, such as for example kaolin or bentonite.
  • surfactants at a rate of 2 to 20% by weight of the granule of which more than half is, for example, constituted by at least one dispersing agent, essentially anionic, such as a polynaphthalene alkaline or alkaline earth sulfonate or an alkaline or alkaline earth lignosulfonate, the remainder being nonionic or anionic wetting agents such as an alkali or alkaline earth alkyl naphthalene sulfonate.
  • dispersing agent essentially anionic, such as a polynaphthalene alkaline or alkaline earth sulfonate or an alkaline or alkaline earth lignosulfonate, the remainder being nonionic or anionic wetting agents such as an alkali or alkaline earth alkyl naphthalene sulfonate.
  • the granule according to the invention can be prepared by mixing the necessary ingredients and then granulation according to several techniques known per se (bezel, fluid bed, atomizer, extrusion, etc.). It generally ends with a crushing followed by sieving to the particle size chosen within the limits mentioned above. Can also be used granules obtained as above and then impregnated with a composition containing the active material.
  • Example GDI Dispersible granules
  • a mixer 90% by weight of active material and 10% urea pearls are mixed. The mixture is then ground in a pin mill. A powder is obtained which is moistened with approximately 8% by weight of water. The wet powder is extruded in a perforated roller extruder. A granule is obtained which is dried, then crushed and sieved, so as to keep respectively only the granules of a size between 150 and 2000 microns.
  • Example QD2 Dispersible granules In a mixer, the following constituents are mixed: - active material 75%
  • This mixture is granulated in a fluid bed, in the presence of water, then dried, crushed and sieved so as to obtain granules of size between 0.15 and 0.80 mm.
  • These granules can be used alone, in solution or dispersion in water so as to obtain the desired dose. They can also be used to prepare combinations with other active materials, in particular antibacterials, the latter being in the form of wettable powders, or aqueous granules or suspensions.
  • the compositions suitable for storage and transport they more advantageously contain from 0.5 to 95% (by weight) of active substance.
  • the invention also relates to a method for the therapeutic antibacterial treatment for humans or animals by administration of an effective dose of the peptide according to the invention, in free form or, where appropriate, in the form of addition salts. with an acid, of Andallic salts or of addition salts with a pharmaceutically acceptable base, in the pure state or in the form of a composition in which it is associated with any other pharmaceutically compatible product, which may be inert or physiologically active.
  • the medicaments according to the invention can be administered by oral, parenteral, rectal or topical route.
  • compositions for oral administration tablets, pills, powders (especially in gelatin capsules or cachets) or granules can be used.
  • the active product according to the invention is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica.
  • these compositions can also comprise other substances, for example one or more lubricants such as magnesium stearate or talc, a colorant, a coating (dragees) or a varnish.
  • compositions for oral administration use may be made of pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs containing inert diluents such as water, ethanol, glycerol, vegetable oils or the like. paraffin oil.
  • inert diluents such as water, ethanol, glycerol, vegetable oils or the like. paraffin oil.
  • These compositions can also include other substances, for example wetting, sweetening, thickening, flavoring or stabilizing products.
  • the sterile compositions for parenteral administration may preferably be aqueous or non-aqueous solutions, suspensions or emulsions.
  • solvent or vehicle water, propylene glycol, polyethylene glycol, vegetable oils, in particular olive oil, suitable organic esters can be used.
  • These compositions can also contain adjuvants, in particular wetting agents, isotonizers, emulsifiers, dispersants and stabilizers. Sterilization can be done in different ways, for example by aseptic filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They can also be prepared in the form of sterile solid compositions, which can be dissolved at the time of use in a sterile injectable medium.
  • the compositions for rectal administration are suppositories or rectal capsules, which contain, in addition to the active peptide, excipients such as cocoa butter, semi-synthetic glycerides or polyethylene glycols.
  • compositions for topical administration can be, for example, creams, ointments, lotions, eye drops, mouthwashes, nasal drops or aerosols.
  • the peptide according to the invention is particularly useful in antibacterial treatments.
  • the doses depend on the desired effect and on the duration of the treatment; they are generally between 50 and 1000 mg per day orally for an adult in one or more drills. In general, the doctor will determine the dosage he considers most appropriate based on age, weight and all other factors specific to the subject to be treated.
  • Example A is given without implied limitation illustrating the compositions according to the invention.
  • Tablets containing 50 mg of active peptide having the following composition are prepared according to the usual technique:
  • a solution for injection containing 20 mg of active peptide having the following composition is prepared: - androctonine peptide M 2 22.4 mg

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
EP97905217A 1996-02-16 1997-02-17 Peptide antibacterien et antifongique Withdrawn EP0882063A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9602168A FR2745004B1 (fr) 1996-02-16 1996-02-16 Peptide antibacterien et antifongique
FR9602168 1996-02-16
PCT/FR1997/000295 WO1997030082A2 (fr) 1996-02-16 1997-02-17 Peptide antibacterien et antifongique

Publications (1)

Publication Number Publication Date
EP0882063A2 true EP0882063A2 (fr) 1998-12-09

Family

ID=9489456

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97905217A Withdrawn EP0882063A2 (fr) 1996-02-16 1997-02-17 Peptide antibacterien et antifongique

Country Status (15)

Country Link
US (2) US6127336A (hu)
EP (1) EP0882063A2 (hu)
JP (1) JP2000505440A (hu)
KR (1) KR19990082596A (hu)
CN (1) CN1216047A (hu)
AU (1) AU722891B2 (hu)
BR (1) BR9707292A (hu)
CA (1) CA2245518A1 (hu)
EA (1) EA000843B1 (hu)
FR (1) FR2745004B1 (hu)
HU (1) HUP9900935A3 (hu)
IL (1) IL125778A (hu)
PL (1) PL328579A1 (hu)
TR (1) TR199801582T2 (hu)
WO (1) WO1997030082A2 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2767537B1 (fr) * 1997-08-20 2001-07-13 Rhone Poulenc Agrochimie Gene codant pour l'androctonine, vecteur le contenant et plantes transformees obtenues resistantes aux maladies
FR2777568B1 (fr) 1998-04-15 2002-10-31 Rhone Poulenc Agrochimie Gene codant pour l'heliomicine, proteine obtenue, vecteur le contenant, organismes transformes obtenus et procede de preparation
US20040029167A1 (en) * 1999-03-22 2004-02-12 Bernard Fritig Inducible COMT_II promoter, chimeric gene containing same and plants transformed therewith
US7015309B1 (en) 1999-06-23 2006-03-21 The Wistar Institute Of Anatomy And Biology Pyrrhocoricin-derived peptides, and methods of use thereof
WO2000078956A1 (en) * 1999-06-23 2000-12-28 The Wistar Institute Of Anatomy And Biology Novel pyrrhocoricin-derived peptides, and methods of use thereof
US20030108957A1 (en) * 2002-07-19 2003-06-12 The Wistar Institute Of Anatomy And Biology Biocidal molecules, macromolecular targets and methods of production and use
FR2815969B1 (fr) 2000-10-30 2004-12-10 Aventis Cropscience Sa Plantes tolerantes aux herbicides par contournement de voie metabolique
US7414173B1 (en) 2002-07-12 2008-08-19 E.I. Du Pont De Nemours And Company Isolated nucleic acid molecules encoding orally active androctonus amoreuxi pesticidal biopeptides
FR2844142B1 (fr) 2002-09-11 2007-08-17 Bayer Cropscience Sa Plantes transformees a biosynthese de prenylquinones amelioree
FR2848064B1 (fr) * 2002-12-06 2006-01-13 Bayer Cropscience Sa Plantes legumineuses transplastomiques fertiles
FR2848570B1 (fr) 2002-12-12 2005-04-01 Bayer Cropscience Sa Cassette d'expression codant pour une 5-enol pyruvylshikimate-3-phosphate synthase (epsps) et plantes tolerantes aux herbicides la contenant
CN1950396A (zh) * 2004-02-24 2007-04-18 联邦科学技术研究组织 抗真菌肽
CA2681921A1 (en) * 2007-03-26 2008-10-02 Commonwealth Scientific And Industial Research Organisation Peptides with anitfungal activity
CN101063103B (zh) * 2007-04-26 2010-05-19 武汉大学 一种海南斑等蝎抗菌肽及制备方法和应用
AR074941A1 (es) 2009-01-07 2011-02-23 Bayer Cropscience Sa Plantas transplastomicas exentas de marcador de seleccion
AU2011212538B2 (en) 2010-02-02 2014-12-04 BASF Agricultural Solutions Seed US LLC Soybean transformation using HPPD inhibitors as selection agents
CU24055B1 (es) * 2010-09-27 2014-12-26 Grupo Empresarial De Producciones Biofarmacéuticas Y Químicas Labiofam Composiciones farmacéuticas de veneno de escorpión rhopalurus junceus
CN103421100B (zh) * 2012-05-22 2015-11-18 中国科学院动物研究所 一种抗菌肽及其制备方法和应用
CN105254722B (zh) * 2015-11-03 2019-01-25 南京农业大学 一种抗菌肽fk及其制备方法和应用
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
FR3071505B1 (fr) 2017-09-22 2022-04-08 Capsum Capsules bactericides ou bacteriostatiques ou antifongiques comprenant des cellules vivantes et leurs utilisations
JPWO2022215495A1 (hu) * 2021-04-08 2022-10-13
WO2024141638A1 (en) * 2022-12-30 2024-07-04 Biotalys NV Self-emulsifiable concentrate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9730082A2 *

Also Published As

Publication number Publication date
EA000843B1 (ru) 2000-04-24
JP2000505440A (ja) 2000-05-09
TR199801582T2 (xx) 1998-11-23
KR19990082596A (ko) 1999-11-25
PL328579A1 (en) 1999-02-01
BR9707292A (pt) 1999-07-20
US6331522B1 (en) 2001-12-18
IL125778A (en) 2001-05-20
FR2745004B1 (fr) 1998-03-27
WO1997030082A2 (fr) 1997-08-21
WO1997030082A3 (fr) 1997-09-25
CA2245518A1 (fr) 1997-08-21
EA199800731A1 (ru) 1999-02-25
CN1216047A (zh) 1999-05-05
HUP9900935A2 (hu) 1999-07-28
IL125778A0 (en) 1999-04-11
US6127336A (en) 2000-10-03
AU1884397A (en) 1997-09-02
AU722891B2 (en) 2000-08-10
HUP9900935A3 (en) 2001-08-28
FR2745004A1 (fr) 1997-08-22

Similar Documents

Publication Publication Date Title
EP0882063A2 (fr) Peptide antibacterien et antifongique
FR2773155A1 (fr) Nouveaux composes fongicides
EP0307992B1 (fr) Compositions contenant des produits pesticides biosynthétiques, procédés pour leur production et leur utilisation
EP0249566B1 (fr) Compositions bactéricides à base de dérivés de l'acide phosphoreux
EP0970609A1 (fr) Mélanges herbicides à base d'aclonifen et d'un composé 3-phenylpyrazole
EP0599749A1 (fr) Dérivés de 2-alkoxy 2-imidazoline-5 ones fongicides
WO1994001410A1 (fr) Derives de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides
FR2732345A1 (fr) Peptide antibacterien
DE60013147T2 (de) Caspase-hemmer
FR2725992A1 (fr) Peptide antifongique
FR2733237A1 (fr) Peptide antibacterien et antifongique
EP0663148B1 (fr) Composition fongicide à base d'un 3,5-dichloranilide comme l'iprodione et de bromocunazole
EP0223719A1 (fr) Composition fongicide à base d'un dérivé de l'acide phosphoreux
EP0840549A1 (fr) Associations insecticides d'un oxime carbamate avec un insecticide a groupe pyrazole, pyrrole ou phenylimidazole
EP0249567A2 (fr) Dérivés propargyloxybenzènes, leur préparation et compositions fongicides les contenant
CH642819A5 (en) Process for the agricultural production of ergot
KR20240124177A (ko) 신규한 양친매성 항진균 펩타이드
EP0790770B1 (fr) Melanges herbicides a base de derive 3-phenylpyrazole et de bifenox
JPS625904A (ja) 殺菌組成物
EP0316245A1 (fr) Dérivés nicotiniques fongicides
JPS625905A (ja) 殺菌組成物
JPS625903A (ja) 殺菌組成物
FR2773153A1 (fr) Nouveaux composes fongicides
JPS625906A (ja) 殺菌組成物
JPS6124505A (ja) 殺菌組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980916

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AVENTIS CROPSCIENCE S.A.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER CROPSCIENCE S.A.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: ANTIFUNGAL AND ANTIBACTERIAL PEPTIDE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER CROPSCIENCE S.A.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040413